VIALE-A included patients with various comorbidities and different mutational and cytogenetic profiles, including IDH1/2 and FLT3 1,3 

Baseline characteristics 1
Characteristic VEN+AZA (N=286) PBO+AZA (N=145)

Age, years; median (range)

76 (49, 91) 76 (60, 90)
Race; %    
White 76 75
Black or African American 1 1.4
Asian 23 23
Male; % 60 60
ECOG performance status; %    
0-1 55 56
2 40 41
3 5.6 3.4
Bone marrow blast; %    
<30% 30 28
≥30% to <50% 21 23
≥50% 49 49
Disease history; %    
De novo AML 75 76
Secondary AML 25 24
Cytogenetic risk detected*; %    
Intermediate 64 61
Poor 36 39
Mutation analyses detected; n/N (%)    
IDH1 or IDH2 61/245 (25) 28/127 (22)
IDH1 23/245 (9.4) 11/127 (8.7)
IDH2 40/245 (16) 18/127 (14)
FLT3 29/206 (14) 22/108 (20)
NPM1 27/163 (17) 17/86 (20)
TP53 38/163 (23) 14/86 (16)

*Per the 2016 National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
Number of evaluable bone marrow aspirate (BMA) specimens received at baseline.

VEN=VENCLEXTA; AZA=azacitidine; PBO=placebo; IDH=isocitrate dehydrogenase; FLT=fms-like tyrosine kinase; NPM=nucleophosmin; TP53=tumor protein p53.

Previous — See VIALE-A study design

See overall survival results — Next